Literature DB >> 23321632

Targeted prostate biopsies for a histogram of the index lesion.

Osamu Ukimura1, Inderbir S Gill.   

Abstract

PURPOSE OF REVIEW: Knowledge of the three-dimensional location and contour of the clinically significant cancer (index cancer), and its proximity to the critical anatomical structures (such as prostate capsule, external sphincter, neurovascular bundle) has significant impact on preoperative and intraoperative decision-making during radical prostatectomy and focal therapy treatments. RECENT
FINDINGS: Modern image-targeted biopsy techniques can provide increasingly accurate information about the location and other characteristics of the index cancer lesion. Although resolution of modern imaging may characterize glandular level differences between malignant and benign tissues, their accuracy is not yet at the cellular level. As such, imaging alone can likely overestimate or underestimate the volume of the index lesion. Superimposition of biopsy-proven histologic data can allow creation of a more precise histogram of the index lesion.
SUMMARY: Superimposing the recorded needle biopsy trajectories upon magnetic resonance/transrectal ultrasound images can provide a more accurate three-dimensional picture of the location and size of the histologically proven dominant cancer lesion. A virtual histogram of the index lesion can thus be created. This may have implications for radical surgery, focal therapy, and active surveillance on a 'per-lesion' strategy.

Entities:  

Mesh:

Year:  2013        PMID: 23321632     DOI: 10.1097/MOU.0b013e32835d4dc8

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  3 in total

1.  Multimodal Imaging in Focal Therapy Planning and Assessment in Primary Prostate Cancer.

Authors:  Hossein Jadvar
Journal:  Clin Transl Imaging       Date:  2017-04-10

2.  Identifying aggressive prostate cancer foci using a DNA methylation classifier.

Authors:  Kamilla Mundbjerg; Sameer Chopra; Mehrdad Alemozaffar; Christopher Duymich; Ranjani Lakshminarasimhan; Peter W Nichols; Manju Aron; Kimberly D Siegmund; Osamu Ukimura; Monish Aron; Mariana Stern; Parkash Gill; John D Carpten; Torben F Ørntoft; Karina D Sørensen; Daniel J Weisenberger; Peter A Jones; Vinay Duddalwar; Inderbir Gill; Gangning Liang
Journal:  Genome Biol       Date:  2017-01-12       Impact factor: 13.583

3.  A prognostic hypoxia gene signature with low heterogeneity within the dominant tumour lesion in prostate cancer patients.

Authors:  Unn Beate Salberg; Vilde Eide Skingen; Christina Sæten Fjeldbo; Tord Hompland; Harald Bull Ragnum; Ljiljana Vlatkovic; Knut Håkon Hole; Therese Seierstad; Heidi Lyng
Journal:  Br J Cancer       Date:  2022-03-24       Impact factor: 9.075

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.